B cell depletion impairs vaccination-induced CD8 T cell responses in a type I interferon-dependent manner.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Guzmán, Carlos Alberto
Schmidt, Reinhold E
MetadataShow full item record
AbstractObjectives: The monoclonal anti-CD20 antibody rituximab is frequently applied in the treatment of lymphoma as well as autoimmune diseases and confers efficient depletion of recirculating B cells. Correspondingly, B cell-depleted patients barely mount de novo antibody responses during infections or vaccinations. Therefore, efficient immune responses of B cell-depleted patients largely depend on protective T cell responses. Methods: CD8+ T cell expansion was studied in rituximab-treated rheumatoid arthritis (RA) patients and B cell-deficient mice on vaccination/infection with different vaccines/pathogens. Results: Rituximab-treated RA patients vaccinated with Influvac showed reduced expansion of influenza-specific CD8+ T cells when compared with healthy controls. Moreover, B cell-deficient JHT mice infected with mouse-adapted Influenza or modified vaccinia virus Ankara showed less vigorous expansion of virus-specific CD8+ T cells than wild type mice. Of note, JHT mice do not have an intrinsic impairment of CD8+ T cell expansion, since infection with vaccinia virus induced similar T cell expansion in JHT and wild type mice. Direct type I interferon receptor signalling of B cells was necessary to induce several chemokines in B cells and to support T cell help by enhancing the expression of MHC-I. Conclusions: Depending on the stimulus, B cells can modulate CD8+ T cell responses. Thus, B cell depletion causes a deficiency of de novo antibody responses and affects the efficacy of cellular response including cytotoxic T cells. The choice of the appropriate vaccine to vaccinate B cell-depleted patients has to be re-evaluated in order to efficiently induce protective CD8+ T cell responses.
CitationAnn Rheum Dis. 2021 Jul 5:annrheumdis-2021-220435. doi: 10.1136/annrheumdis-2021-220435. Epub ahead of print.
AffiliationTWINCORE, Zentrum für experimentelle und klinische Infektionsforschung GmbH,Feodor-Lynen Str. 7, 30625 Hannover, Germany.; HZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.
PublisherBMJ Publishing Group
JournalAnnals of the rheumatic diseases
The following license files are associated with this item:
- Creative Commons
- Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.
- Authors: Altenburg AF, van de Sandt CE, van Trierum SE, De Gruyter HLM, van Run PRWA, Fouchier RAM, Roose K, Saelens X, Volz A, Sutter G, de Vries RD, Rimmelzwaan GF
- Issue date: 2016 Nov 15
- Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara.
- Authors: Volz A, Langenmayer M, Jany S, Kalinke U, Sutter G
- Issue date: 2014 Sep
- Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice.
- Authors: Altenburg AF, Magnusson SE, Bosman F, Stertman L, de Vries RD, Rimmelzwaan GF
- Issue date: 2017 Oct
- Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses.
- Authors: Kamlangdee A, Kingstad-Bakke B, Osorio JE
- Issue date: 2016 Aug 1
- Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination.
- Authors: Muller RB, Maier R, Hoschler K, Zambon M, Ludewig B, Herrmann M, Schulze-Koops H, von Kempis J
- Issue date: 2013 Sep-Oct